Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings

Executive Summary

Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.

Advertisement

Related Content

Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'
Billions On The Line With Celgene’s Partnered Pipeline
Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus
Carrick Therapeutics Lays Foundation For 'Leading Oncology Business'
US/China-based MicuRx Gets $55m Series C Funding For MRX-I Antibiotic
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Artios Launches With £25m To Study ‘PARP-esque’ DNA Damage Response Inhibitors
Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics
BioNotebook: PhaseBio closes $40m Series C round led by AstraZeneca, plus five other VC financings
Cancer drug start-up Peloton raises $18M

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel